{"authors":["Associated Press"],"date_download":"2018-10-23 01:41:46","date_modify":"2018-10-23 01:41:46","date_publish":"2016-01-29 15:45:15","description":"NORTH CHICAGO, Ill. (AP) — Soaring U.S. sales of the blockbuster anti-inflammatory drug Humira helped AbbVie post a profit of $1.52-billion for the fourth qu...","filename":"data/vaneerConsumption/AbbViecutscoststurnsprofitthatmeets4Qexpectations.json","image_url":"https://i.dailymail.co.uk/i/pix/2016/01/29/article-urn:publicid:ap.org:6b6dded8bea9865fcfdb9d4cec3d99fc-4PuZeKVXE7cd9005b2c876bd8196-504_636x382.jpg","language":"en","localpath":"/home/avsp_here/news-please-repo//data/2018/10/22/dailymail.co.uk/wires_ap_article-3422779_AbbVie-meets-4Q-profit-forecasts_1540258906.html","title":"AbbVie cuts costs, turns profit that meets 4Q expectations","title_page":"AbbVie cuts costs, turns profit that meets 4Q expectations | Daily Mail Online","title_rss":"NULL","source_domain":"dailymail.co.uk","text":"AbbVie cuts costs, turns profit that meets 4Q expectations\nNORTH CHICAGO, Ill. (AP) — Soaring U.S. sales of the blockbuster anti-inflammatory drug Humira helped AbbVie post a profit of $1.52-billion for the fourth quarter and match Wall Street's earnings expectations.\nThe drugmaker said Friday that U.S. sales of Humira jumped 21 percent in the quarter, driven by growth in all of its major treatment categories: rheumatology, dermatology and gastroenterology. Worldwide, Humira brought in $3.72 billion in sales during the quarter and more than $14 billion during the year.\nCost-cutting also helped AbbVie Inc. in the quarter. The North Chicago, Illinois, company's selling, general and administrative expenses dropped 48 percent to $1.74 billion.\nFILE - This Jan. 24, 2015, file photo, shows the exterior of AbbVie, in Lake Bluff, Ill. AbbVie reports financial results, Friday, Jan. 29, 2016. (AP Photo/Nam Y. Huh, File)\nAbbVie also pulled in $554 million from its hepatitis C treatment Viekira, which launched late in 2014.\nOverall, AbbVie recorded adjusted earnings of $1.13 per share in the final quarter of 2015, while revenue climbed more than 17 percent to $6.4 billion.\nAnalysts forecast, on average, $6.45 billion in revenue, according to Zacks Investment Research\nAbbVie booked an $810-million loss in the final quarter of 2014, as a $2.2-billion breakup fee and other expenses from its abandoned merger with Shire PLC weighed on results.\nFor 2016, the drugmaker expects adjusted earnings of between $4.90 to $5.10 per share.\nAnalysts forecast, on average, earnings of $5.01 per share, according to FactSet.\nShares of AbbVie dropped 2.2 percent, or $1.24, to $53.62 in morning trading Friday. The stock has fallen almost 6 percent since the beginning of the year, while the Standard & Poor's 500 index has declined slightly more than 7 percent.\n_____\nElements of this story were generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ABBV at http://www.zacks.com/ap/ABBV\n_____","url":"https://www.dailymail.co.uk/wires/ap/article-3422779/AbbVie-meets-4Q-profit-forecasts.html"}
